Attention! Are you ready to dive into the world of managing ADHD in adults? It's a topic that's become increasingly relevant, yet often misunderstood. Today, we're joined by Professor Shuichi Suetani, a renowned expert in the field, to shed some light on this complex issue.
Professor Suetani, a fellow Queenslander, has witnessed a remarkable shift in the landscape of psychiatric practice over the past decade. When he began his training, ADHD in adults was virtually non-existent, but now it's a dominant concern for many patients.
Let's start with the basics. ADHD affects a significant portion of adults, around 3-5%, according to studies. However, as Dr. Coleman wisely cautions, these studies often cast a wide net, while therapeutic intervention studies focus on the most severe cases. This means the 3-5% figure might not fully represent the reality of ADHD treatment.
So, when an adult walks into Professor Suetani's practice with potential ADHD symptoms, what happens next? The initial psychiatric assessment is crucial. Professor Suetani emphasizes the importance of not jumping to conclusions. With so many psychiatric diagnoses featuring inattentiveness as a key symptom, it's easy to misdiagnose. In fact, studies suggest that a whopping 80% of ADHD patients have additional comorbid psychiatric conditions.
This brings us to the first key difference between adult and childhood ADHD. Adults are more likely to have other mental health issues or physical conditions, such as anemia or hypothyroidism, which can cause inattentiveness. Additionally, adults have had more time to develop coping strategies, which can either mask or exacerbate their symptoms.
But here's where it gets controversial... Professor Suetani points out that ADHD is not just about symptoms; it's about the environment and how it impacts behavior. This is a crucial aspect often overlooked.
When it comes to treatment, we must consider cardiovascular risks. The Bi-national ADHD Association provides clear guidelines on when to refer patients to cardiologists. Most ADHD medications can increase blood pressure and heart rate in the short term, which might be concerning for some individuals.
And this is the part most people miss... The risk profile differs significantly between adults and children. An adult in their 40s might have a different set of concerns compared to a 5-year-old starting psychostimulant medication. Specific cardiac symptoms to watch out for include shortness of breath, fainting, palpitations, and chest pain.
Now, let's talk about the medications themselves. Professor Suetani simplifies it for us: there are four main options - psychostimulants and non-psychostimulants. Psychostimulants are further divided into methylphenidate and amphetamines, with various trade names and formulations. Non-psychostimulants include atomoxetine and guanfacine.
Professor Suetani's approach is straightforward: start with psychostimulants if there are no contraindications, then move to other psychostimulants if needed, and finally, consider non-psychostimulants. Atomoxetine is often the go-to choice for adults.
But what about side effects? We've already covered the cardiovascular risks. Psychostimulants can also increase the risk of serotonin syndrome when combined with other medications. And let's not forget about the potential for misuse, especially with illicit substances.
Once a patient starts medication, we need to monitor their response. Professor Suetani suggests using the adult ADHD self-report scale to track symptom changes over time. It's also crucial to watch for side effects, especially cardiovascular ones, weight changes, and psychiatric symptoms like anxiety and sleep disturbances.
But what if the patient isn't improving? Professor Suetani emphasizes the provisional nature of psychiatric diagnoses, especially in adulthood where symptoms can be nonspecific and comorbidities are common. It's essential to question whether the diagnosis is correct and whether the right treatment is being administered.
And this brings us to the long-term benefits of ADHD medication. Studies on opioids in chronic pain suggest short-term benefits, but what about ADHD drugs in adults? Professor Suetani highlights the lack of long-term evidence, especially for older adults.
So, what's the takeaway? ADHD medications can have a positive placebo effect, and they are effective in managing symptoms. But as Professor Suetani wisely advises, "pills don't teach skills." Medication is just one part of a wider range of changes needed to treat ADHD. It's an opportunity to make life better, but it's not a silver bullet.
There you have it, folks! A deep dive into the pharmacological management of ADHD in adults. We hope this has been informative and sparked some thought-provoking discussions. Don't forget to share your thoughts and experiences in the comments below!
Professor Shuichi Suetani has received honoraria and advisory fees from various sources, as disclosed at the end of the podcast.
